Photo of Lisa Edelmann

Lisa Edelmann

  • ASSOCIATE PROFESSOR Genetics and Genomic Sciences
Print ProfilePrint Profile


  • Albert Einstein College of Medicine

  • Albert Einstein College of Medicine

  • Mount Sinai School of Medicine


The molecular genetics laboratory is focused on the detection of carriers for specific genetic diseases.  In particular, the laboratory has been a leading provider of genetic testing for the Ashkenazi Jewish (AJ) community living in the greater New York metropolitan area.  This population is at increased risk for a number of autosomal recessive diseases that are lethal in childhood or are associated with significant mental or physical disability.  These diseases generally have a limited number of specific mutations and are present in greater than 95 persent of affected patients, due to genetic drift and/or selection.  The laboratory also offers pre- and postnatal mutation scanning for Noonan syndrome.  In addition, we have recently validated a panel of cytochrome P450 variants for the detection of individuals with genotypes that may require dosage adjustments for specific medications.  Research in the laboratory is focused on population screening of Ashkenazi Jewish samples to accurately determine carrier frequencies and allele distributions and assess whether certain mutations or variations may confer increased risk for specific adult-onset diseases.

The molecular cytogenetics laboratory offers Fluorescence in Situ Hybridization (FISH) for a number of chromosome rearrangement disorders, including DiGeorge syndrome, Williams syndrome, Prader Willi and Angelman syndromes, Wolf-Hirschhorn syndrome Cri-du-Chat syndrome, Smith Magenis syndrome and Miller-Dieker syndrome.  We are currently developing testing panels using multiplex ligation-dependent probe amplification (MLPA) and targeted array CGH (Comparative Genomic Hybridization) to increase our ability to clinically detect rearrangements that are not visible by standard karyotype analysis but involve genomic copy number changes. Research in the molecular cytogenetics laboratory is focused on chromosome rearrangement disorders and their mechanism of generation. Most chromosome rearrangements occur sporadically in the population at a specific frequency, depending on the disorder. The combined frequency of chromosome rearrangements, balanced and unbalanced, including translocations, deletions, duplications and inversions is estimated at 1 in 300 live births. For many of these disorders, genomic architecture plays an important role in susceptibility to rearrangement. We are currently investigating the mechanism that generates the isodicentric Xq chromosome (idic(Xq)), a spontaneously occurring chromosomal aberration that is present in 18 percent of Turner Syndrome cases, and is the most common constitutional isochromosome in humans. We have collected a number of cell lines to delineate the breakpoints of the idic(Xq) in order to better understand how the architecture in the region of Xp11 influences formation of the isochromosome.  Our methods of study include FISH and array CGH, generation of human hamster somatic hybrid cell lines, pulse field gel electrophoresis and long range PCR to amplify across breakpoint junctions. Ultimately, we would like to determine whether specific variations in genomic architecture at the breakpoint regions of recurrent rearrangements confer increased susceptibility to the rearrangement.The laboratory is also involved in a collaborative effort to understand how chromosome rearrangement disorders contribute to autism by investigating the frequency of known micro- deletion and duplication syndromes in autism patients as well as delineating novel de novo rearrangements in autism.


Edelmann L, McInnes LA, Pardo S, Bhatt J, Cohen N, Lauriat T, Ouchanov L, Jimenez Gonzalez P, Manghi ER, Bondy P, Esquivel M, Monge S, Fallas Delgado M, Splendore A, Francke U, Prosnitz A. An atypical deletion of the Williams-Beuren syndrome interval implicates genes associated with defective visuospatial processing and autism. J. Med. Genet 2007; 44: 136-143.

Wei Y, Kane M, Putnum C, Zhang W, Edelmann W, Russell R, Chin L, Kucherlapati R, Kolodner R, Edelmann L. Mutation in the large subunit of replication protein A results in defective DNA double-strand break repair, chromosomal instability and cancer in mice. Nat. Genet 2005; 37: 750-755.

Shanske AL, Edelmann L, Levy B, Gosset P, Kardon NB. Detection of an interstitial deletion of 2q21-22 by high resolution comparative genomic hybridization in a child with multiple congenital anomalies and an apparent balanced translocation. Am. J. Med. Gen 2004; 131A: 29-35.

Kornreich R, Desnick RJ, Edelmann L, Ekstein J. Premarital and prenatal screening for cystic fibrosis: experience in the Ashkenazi Jewish population. Genet. Med 2004; 6: 415-420.

Edelmann L, Hashmi G, Desnick RJ, Kornreich R, Seul M. Cystic fibrosis carrier screening: validation of a novel method using beadchip technology. Genet. Med 2004; 6: 431-438.

Edelmann W, Edelmann L. Loss of DNA mismatch repair function and cancer predisposition in the mouse: animal models for human hereditary non-polyposis colorectal cancer. Am. J. Med. Gen 2004; 129C: 91-99.

Dong J, Edelmann L, Desnick RJ, Kornreich R, Bajwa AM. Familial dysautonomia: detection of the IKBKAP IVS20+6T>C and R696P mutations and frequencies among Ashkenazi Jews. Am. J. Med. Gen 2002; 110: 253-257.

Edelmann L, Kornreich R, Desnick RJ, Dong J. Carrier screening for mucolipidosis type IV in the American Ashkenazi Jewish population. Am. J. Hum. Genet 2002; 70: 1023-1027.

Zinberg R, Desnick RJ, Edelmann L, Kornreich R. Carrier screening in the Ashkenazi Jewish population. Clinics in Perinatology 2001; 28: 367-382.

Edelmann L, Wasserstein MP, Diaz GA, Sansaricq C, Snyderman SE, Kornreich R. Maple syrup urine disease: identification and carrier-frequency determination of a novel founder mutation in the Ashkenazi Jewish population. Am. J. Hum. Genet 2001; 69: 863-868.

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Dr. Edelmann did not report having any of the following types of financial relationships with industry during 2015 and/or 2016: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.

Edit profile in Sinai Central


Atran Berg Laboratory Building Floor 2 Room AB2-25
1428 Madison Avenue
New York, NY 10029

Tel: 212-241-1865